Seeking AlphaCodex · 实盘不做把握 6/10
北京时间·🕒 发布 04:38:10时区推断·⟳ 抓取 04:38:14·⚡ 决策 08-04 04:43:21 +5m07s·84.8 天前
Stoke二季度EPS不及预期但收入高于预期、同比下降32.4%
Q2 GAAP EPS为-0.93美元，较预期低0.15美元；收入933万美元较预期高424万美元，但同比下降32.4%。
📄 原文Seeking Alpha↗ 原文
Stoke Therapeutics GAAP EPS of -$0.93 misses by $0.15, revenue of $9.33M beats by $4.24M
- Stoke Therapeutics press release (STOK): Q2 GAAP EPS of -$0.93 misses by $0.15. - Revenue of $9.33M (-32.4% Y/Y) beat…
不做 Stoke Therapeutics（STOK.US）
EPS miss与收入beat相互抵消，且收入来自合作义务确认、可持续性弱，不开多也不开空。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-08-03 · 扩散 medium · price-in 风险 medium ↗
关键理由
- Q2 GAAP EPS为-0.93美元，较预期低0.15美元；收入933万美元较预期高424万美元，但同比下降32.4%。
- 收入来自Acadia和Biogen合作及许可协议的合同义务确认，通常较为一次性，不能直接外推为产品商业化增长。
主要风险
- EPS miss和收入同比下降偏负面，但收入又显著高于预期，净影响不够清晰。
工具调用 · 历史记录,结果未知(1 种)
- stock_quote · 结果未知
原文全文
展开原文 · 402 字
- Stoke Therapeutics press release (STOK): Q2 GAAP EPS of -$0.93 misses by $0.15.
- Revenue of $9.33M (-32.4% Y/Y) beats by $4.24M.
- Revenue recognized for the three months ended June 30, 2026, was $9.3 million, a decrease from $13.8 million for the same period in 2025. Revenue is generated from satisfying contractual obligations of the collaboration and licensing agreements with Acadia and Biogen.
- Revenue of $9.33M (-32.4% Y/Y) beats by $4.24M.
- Revenue recognized for the three months ended June 30, 2026, was $9.3 million, a decrease from $13.8 million for the same period in 2025. Revenue is generated from satisfying contractual obligations of the collaboration and licensing agreements with Acadia and Biogen.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。